Quince Therapeutics, Inc.
$ 30.20
2.23%
07 Aug - close price
- Market Cap 29,534,500 USD
- Current Price $ 30.20
- High / Low $ 30.77 / 29.25
- Stock P/E N/A
- Book Value 22.73
- EPS -210.00
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -1.93 %
- 52 Week High 910.00
- 52 Week Low 15.10
About
Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$82.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-10 | 2026-03-03 | 2025-11-12 | 2025-08-11 | 2025-05-13 | 2025-03-24 | 2024-11-13 | 2024-08-13 | 2024-05-13 | 2024-03-10 | 2023-11-14 | 2023-08-03 |
| Reported EPS | -152 | -0.4094 | -50 | -65.02 | -0.34 | -56 | -26 | -0.6434 | -0.2171 | -0.22 | -0.1483 | -0.136 |
| Estimated EPS | -45 | -0.1833 | -44.5 | -46.5 | -0.23 | -20 | -20 | None | None | -0.28 | None | 0 |
| Surprise | -107 | -0.2261 | -5.5 | -18.52 | -0.11 | -36 | -6 | 0 | 0 | 0.06 | 0 | -0.136 |
| Surprise Percentage | -237.7778% | -123.3497% | -12.3596% | -39.828% | -47.8261% | -180% | -30% | None% | None% | 21.4286% | None% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -33.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNCX
2026-08-04 19:09:48
A Schedule 13G filing reveals that Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, collectively reported a beneficial ownership of 5.6% in Quince Therapeutics (QNCX). This ownership amounts to 55,173 shares of common stock, based on 977,963 shares outstanding following a reverse stock split on June 29, 2026. The reporting persons have shared voting and dispositive power over these shares, but Squadron Capital Management, LLC and its partners disclaim beneficial ownership under Rule 13d-4.
2026-08-02 20:12:33
Quince Therapeutics announced a leadership transition following conditional resignations from its CEO and COO, effective after a special shareholder meeting on September 25, 2026, pending shareholder approval of proposals related to the Orphai acquisition. The company's board has approved conditional appointments of Orphai veterans to key leadership roles, signaling a shift of operational control to the acquired team. Analysts currently rate QNCX stock as a Buy with a $99.00 price target, although Spark, TipRanks’ AI Analyst, views it as Neutral due to weak financial fundamentals despite positive corporate events.
2026-08-01 04:40:41
This article reports on the filing of Form PRE 14A by Quince Therapeutics Inc. for August 1. The document is available through Investing.com, a financial markets platform.
2026-08-01 04:09:22
This article reports on the filing of Form PRE 14A by Quince Therapeutics Inc. on August 1st. The brief note also includes the company's stock symbol QNCX and its current performance of +1.56%.
2026-08-01 03:40:53
Quince Therapeutics Inc (NASDAQ: QNCX) stockholders plan to sell 15.47 million shares, a move that the company itself will not participate in. Despite a high Price-to-Sales ratio of 22.87, the pre-revenue biotech firm has a low GF Score™ of 25 out of 100, indicating significant operational challenges and unprofitability. This large-scale selling and cautious sentiment from premium gurus suggest high risk for investors.
2026-08-01 03:40:53
Quince Therapeutics (QNCX) has filed to register 15.5 million shares of Common Stock for resale by existing selling stockholders. These shares are linked to the company's acquisition of Orphai Therapeutics and a 2026 private placement. Quince will not receive direct proceeds from the resale but may benefit if associated warrants are exercised.
